Synthesis and biological evaluation of thiophenylbenzofuran derivatives as potential P-glycoprotein inhibitors
- Eur J Med Chem. 2020 Sep 1;201:112422. doi: 10.1016/j.ejmech.2020.112422.
- 1. School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan; Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan.
- 2. School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan.
- 3. Department of Biological Science and Technology, I-Shou University, Kaohsiung, Taiwan.
- 4. School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan; Department of Pharmacy, Sunshine Psychiatric Hospital, Taichung, Taiwan.
- 5. School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan; Drug Development Center, China Medical University, Taichung, Taiwan. Electronic address: [email protected].
P-glycoprotein (P-gp) overexpression is a major mechanism by which Cancer cells acquire the multidrug resistance (MDR) phenotype, and is associated with poor clinical outcome in patients. In an effort to develop MDR-reversal agents, we synthesized and evaluated a series of thiophenylbenzofuran derivatives (4-31) as P-gp inhibitors, among which compounds 4, 10, and 14 represented the optimal agent in reversing the MDR phenotype. These P-gp inhibitors were dramatically effective than verapamil in sensitizing the human ABCB1-overexpressing ABCB1/Flp-In™-293 cells and MDR KBvin cells to a series of chemotherapeutic agents, including vincristine and paclitaxel, as manifested by multi-fold decreases in the respective IC50 values to therapeutically attainable levels.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: P-glycoproteinResearch Areas: Cancer